Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers

Vaccine

Volumn 20, Issue 5-6, 2001, Pages 845-852

  Bumann, D ^a   Metzger, W G ^a   Mansouri, E ^b   Palme, O ^a   Wendland, M ^a   Hurwitz, R ^a   Haas, G ^a   Aebischer, T ^a   Von Specht, B U ^b   Meyer, T F ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cellular immune responses; Clinical trial; Oral vaccination

Indexed keywords

BACTERIAL ENZYME; GAMMA INTERFERON; RECOMBINANT VACCINE; TYPHOID VACCINE; UREASE;

ADULT; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BACTERIUM CARRIER; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLA ENTERICA; SEROCONVERSION; T LYMPHOCYTE; VACCINATION; VOLUNTEER;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; B-LYMPHOCYTES; BACTERIAL VACCINES; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION; HELICOBACTER PYLORI; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MALE; SAFETY; SALMONELLA TYPHI; T-LYMPHOCYTES; UREASE; VACCINES, SYNTHETIC;

EID: 0035852273     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00391-7     Document Type: Article

References (33)

1. Helicobacter pylori infection and the pathogenesis of duodenal ulceration
2. Immunobiology of Helicobacter pylori infection
3. Antimicrobial resistance in Helicobacter pylori: A global overview
4. What is the role for vaccination in Helicobacter pylori?
5. Host response and vaccine development to Helicobacter pylori infection
6. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses
7. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies
8. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease
9. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults
10. The attenuated Salmonella vaccine approach for the control of Helicobacter pylori-related diseases
11. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B
12. c expressing urease A and B subunits
13. Live attenuated Salmonella: A paradigm of mucosal vaccines
14. Recombinant live Salmonella spp. for human vaccination against heterologous pathogens
15. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers
16. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers
17. Isolation and characterization of Gal E mutant Ty21a of Salmonella typhi: A candidate strain for a live, oral typhoid vaccine
18. + gene: Application to cholera vaccine development
19. Primary structure of the Escherichia coli thyA gene and its thymidylate synthase product
20. Purification and N-terminal analysis of urease from Helicobacter pylori
21. Homing potentials of circulating lymphocytes in humans depend on the site of activation: Oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut
22. Enumeration of IFN-γ-producing human lymphocytes by spot-ELISA. A method to detect lymphokine-producing lymphocytes at the single-cell level
23. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: Evidence for compartmentalization within the common mucosal immune system in humans
24. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection
25. Typhoid fever vaccines: A meta-analysis of studies on efficacy and toxicity
26. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in US volunteers
27. Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis
28. Oral delivery of foreign antigens by attenuated Salmonella: Consequences of prior exposure to the vector strain
29. Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers
30. Effect of preexisting immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar Typhimurium expressing a Porphyromonas gingivalis hemagglutinin
31. Prior immunity to homologous and heterologous Salmonella serotypes suppresses local and systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with Salmonella strains expressing fragment C
32. The immune response to a B-cell epitope delivered by Salmonella is enhanced by prior immunological experience
33. Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers